Statistical power of clinical trials increased while effect size remained stable:an empirical analysis of 136,212 clinical trials between 1975 and 2014 by Lamberink, Herm J. et al.
VU Research Portal
Statistical power of clinical trials increased while effect size remained stable
Lamberink, Herm J.; Otte, Willem M.; Sinke, Michel R.T.; Lakens, Daniël; Glasziou, Paul
P.; Tijdink, Joeri K.; Vinkers, Christiaan H.
published in
Journal of Clinical Epidemiology
2018
DOI (link to publisher)
10.1016/j.jclinepi.2018.06.014
document version
Publisher's PDF, also known as Version of record
document license
Article 25fa Dutch Copyright Act
Link to publication in VU Research Portal
citation for published version (APA)
Lamberink, H. J., Otte, W. M., Sinke, M. R. T., Lakens, D., Glasziou, P. P., Tijdink, J. K., & Vinkers, C. H. (2018).
Statistical power of clinical trials increased while effect size remained stable: an empirical analysis of 136,212
clinical trials between 1975 and 2014. Journal of Clinical Epidemiology, 102, 123-128.
https://doi.org/10.1016/j.jclinepi.2018.06.014
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl
Download date: 22. May. 2021
Journal of Clinical Epidemiology 102 (2018) 123e128ORIGINAL ARTICLE
Statistical power of clinical trials increased while effect size remained
stable: an empirical analysis of 136,212 clinical trials between 1975 and
2014
Herm J. Lamberinka,*,1, Willem M. Ottea,b,1, Michel R.T. Sinkeb, Dani€el Lakensc, Paul
P. Glaszioud, Joeri K. Tijdinke, Christiaan H. Vinkersf
aDepartment of Child Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht and Utrecht University, P.O. Box 85090, Utrecht 3508 AB,
The Netherlands
bBiomedical MR Imaging and Spectroscopy group, Center for Image Sciences, University Medical Center Utrecht and Utrecht University, Heidelberglaan
100, Utrecht 3584 CX, The Netherlands
cSchool of Innovation Sciences, Eindhoven University of Technology, Den Dolech 1, Eindhoven 5600 MB, The Netherlands
dCentre for Research in Evidence-Based Practice, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland, Australia
eDepartment of Philosophy, VU University, De Boelelaan 1105, Amsterdam 1081 HV, The Netherlands
fDepartment of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht and Utrecht University, Heidelberglaan 100, Utrecht 3584 CX,
The Netherlands
Accepted 28 June 2018; Published online 5 July 2018AbstractObjectives: To study the statistical power of randomized clinical trials and examine developments over time.
Study Design and Setting: We analyzed the statistical power in 136,212 clinical trials between 1975 and 2014 extracted from meta-
analyses from the Cochrane database of systematic reviews. We determined study power to detect standardized effect sizes, where power
was based on the meta-analyzed effect size. Average power, effect size, and temporal patterns were examined for all meta-analyses and a
subset of significant meta-analyses.
Results: The number of trials with power 80% was low (7%) but increased over time: from 5% in 1975e1979 to 9% in 2010e2014.
In significant meta-analyses, the proportion of trials with sufficient power increased from 9% to 15% in these years (median power
increased from 16% to 23%). This increase was mainly due to increasing sample sizes, while effect sizes remained stable with a median
Cohen’s h of 0.09 (interquartile range 0.04e0.22) and a median Cohen’s d of 0.20 (0.11e0.40).
Conclusion: This study demonstrates that sufficient power in clinical trials is still problematic, although the situation is slowly
improving. Our data encourage further efforts to increase statistical power in clinical trials to guarantee rigorous and reproducible
evidence-based medicine.  2018 Elsevier Inc. All rights reserved.
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The practice of conducting scientific studies with low
statistical power has been consistently criticized across ac-
ademic disciplines [1e5]. Statistical power is the probabil-
ity that a study will detect an effect when there is a true
effect to be detected. Underpowered studies have a low
chance of detecting true effects and have been related to
systematic biases including inflated effect sizes and low
reproducibility [6,7]. Low statistical power has been
demonstrated, among others, in the fields of neuroscience,
economics, and psychology [4,8e10]. For clinical trials
in the field of medicine, the issue of sample size evaluation
inical Epidemiology 102 (2018) 123e128What is new?
Key findings
 Study power in clinical trials is low: 7% of trials
were sufficiently powered (0.8) and 14% had a
power above 0.5; within significant meta-analyses
12% was sufficiently powered and 24% had a po-
wer above 0.5.
 The percentage of sufficiently powered studies
has increased from 5% in 1975e1979 to 9% in
2010e2014.
 Average effect sizes are small and did not increase
over time.
What this adds to what was known?
 Trial sizes and study power increased over time,
although both are still small in most cases.
What is the implication and what should change
now?
 When determining the required sample size of a
clinical trial, small effects should be assumed to
ensure an adequate sample size.
124 H.J. Lamberink et al. / Journal of Cland statistical power is essential because clinical decision-
making and future research are based on these clinical trials
[11,12]. Moreover, low power in clinical trials may be un-
ethical in light of the low informational value from the
outset while exposing participants to interventions with
possible negative (side) effects [1]. Also in medical
research, statistical power is low [3,8], but a systematic
overview of temporal patterns of power, sample sizes, and
effect sizes across medical fields does not exist. In the pre-
sent study, we provide a comprehensive overview of study
power, sample size, and effect size estimates of clinical tri-
als published since 1975, which are included in the Co-
chrane database of systematic reviews, and analyze
emerging trends over time.2. Materials and methods
Data were extracted and calculated from trials included
in published reviews from the second issue of the 2017 Co-
chrane database of systematic reviews. Cochrane reviews
only include meta-analyses if the methodology and out-
comes of the included trials are comparable across study
populations. Meta-analysis data are available for download
in standardized XML-format for those with an institutional
Cochrane Library license. We provide open-source soft-
ware to convert these data and reproduce our entire process-
ing pipeline [13].Trials were selected if they were published after 1974
and if they were included in a meta-analysis based on at
least five trials. Because relatively few studies from
2015 to 2017 were included in our meta-analyses, these
years were excluded. For each individual clinical trial,
publication year, outcome estimates (odds or risk ratio,
risk difference, or standardized mean difference), and
group sizes were extracted. For the main analyses, all
meta-analyses were used; subanalyses were performed
on only the meta-analyses with a reported P-value below
0.05, irrespective of the P-value of the individual trial.
For meta-analyses reporting standardized mean differ-
ences (Cohen’s d), the reported meta-analytic effect size
was used to compute individual study power. For meta-
analyses reporting dichotomous outcomes, meta-analytic
effect size (Cohen’s h) was computed using arcsine trans-
formation of proportions [12]. The main analysis used the
effect size extracted from the meta-analysis, which was
performed as either fixed or random effects as judged by
the authors of that specific Cochrane review. As a sensi-
tivity analysis, we recomputed the meta-analytic effect
size using fixed effects, random effects, and unrestricted
weighted least squares/weighed average of the adequately
powered [14]. This latter method was developed to opti-
mize results from meta-analysis in the context of selective
reporting bias: weighted least squares/weighed average of
the adequately powered performs better than both fixed
and random effects analyses in the context of publication
bias, allows to correct for heterogeneity, and gives similar
results to fixed effects when both are not present [14,15].
Study power was computed in R using the ‘‘pwr’’ package
[16]. Following minimum recommendations for the statis-
tical power of studies [12], comparisons with a power
above or equal to 80% were considered to be sufficiently
powered. Study power, group sizes, and effect sizes over
time were summarized and visualized for all clinical trials.3. Results
Data from 136,212 clinical trials were available, from
11,852 meta-analyses in 1,918 Cochrane reviews. Of these,
77,947 trials (57.2%) were from ameta-analysis with an over-
all P-value below 0.05, from 5,903 meta-analyses (49.8%) in
1,411Cochrane reviews (73.6%). In the original systematic re-
views, fixed effects were used in 55% of meta-analyses,
whereas 45%used randomeffects.Of all trials, 7.3%had a sta-
tistical power of at least 80% (the recommended minimum
[12], which we shall denote as ‘‘sufficient power’’) to detect
an effect size as large as the meta-analyzed effect size; for
the subset of significant meta-analyses this was 12.4%. The
median power (interquartile range [IQR]) was 9% (95% con-
fidence interval [CI] 6%e26%), which was 20% (10%e48%)
for significant meta-analysis (Table 1).
Between 1975e1979 and 2010e2014 the proportion of
sufficiently powered studies rose from 5.1% (4.3e6.1) to
Table 1. Proportion studies with sufficient power and median power
Selected meta-analyses N meta-analyses (N studies) Proportion sufficient (‡0.8) power (95% CI) Median power (IQR)
All 11,852 (136,212) 7.3 (7.2e7.5) 0.09 (0.06e0.26)
Significant 5,903 (77,947) 12.4 (12.2e12.7) 0.20 (0.10e0.48)
Abbreviations: CI, confidence interval; IQR, interquartile range.
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wer changed from 0.09 (IQR 0.06e0.26) to 0.10 (IQR
0.06e0.30) (Fig. 1, left). Within significant meta-
analyses, the rise was more clear: study power increased
with the median rising from 16% (IQR 10e39) to 23%
(IQR 12e55) (Supplementary Figure 1, left), and the pro-
portion of sufficiently powered studies from 9.0%
(7.6e10.6) to 14.7% (13.9e15.5) (Supplementary
Figure 1, top right). This trend is seen across medical dis-
ciplines (Supplementary Figure 2). When the threshold
for sufficient power is set at a minimum of 50% power,
the proportion of trials with sufficient power is still low
but also rising (Supplementary Figure 3). The distribution
of power showed a bimodal pattern, with many low-
powered studies and a small peak of studies with power ap-
proaching 100% (Fig. 1 and Supplementary Figure 1, bot-
tom right).Fig. 1. Statistical power of clinical trials between 1975 and 2014 (left). Ind
is shown in red with interquartile range as error bars. The percentage of adeq
time (top right). The biphasic power distribution of the trials in general is ap
this figure legend, the reader is referred to the Web version of this article.)The average number of participants enrolled in a trial
arm increased over time (Fig. 2, top left). The median
group size in 1975e1979 ranged between 30 and 45; for
the years 2010e2014 the median group size was between
74 and 92. The median effect sizes are summarized in
Table 2; these remained stable over time (Fig. 2). The stan-
dardized effect sizes were small, with a median Cohen’s h
of 0.09 (0.04e0.22) and a median Cohen’s d of 0.20
(0.11e0.40) (Table 2); Figure 3 shows the distribution plots
for these two measures; for the significant meta-analyses,
the median effect sizes were higher (Supplementary
Table 1 and Supplementary Figure 4).
Sensitivity analyses showed robust results regardless of
the method for performing meta-analysis. The proportion
of studies with sufficient power was between 7.2% and
7.5% depending on the method; the median power re-
mained 9% across methods (Supplementary Table 2).ividual comparisons are shown as semitransparent dots. Median power
uately powered trial comparisons (i.e., 80% power) is increasing over
parent (bottom right). (For interpretation of the references to color in
Fig. 2. The number of participants (N ) enrolled in each trial arm, between 1975 and 2014, in red semitransparent dots (top left). Corresponding
effect sizesdclassified in Cochrane reviews as risk difference, standardized mean difference, (Peto) odds ratio or risk ratiodare shown in the re-
maining plots. Median and interquartile data are plotted annually. Years with less than ten studies with the specific measure were omitted from the
plot. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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The present study provides an overview of the statistical
power in 136,212 clinical trials across all medical fields.
Our analyses demonstrate that effect sizes are small, and
that sample sizes of most clinical trials are too small to
detect such an effect. Only 7% of individual trials had suf-
ficient power to detect the observed effect from itsTable 2. Median effect sizes for all meta-analyses









Standardized mean difference 625 (7,210)
Median effect sizes are computed based on the meta-analysis; every m
included trials. To obtain a meaningful summary statistic, effect sizes were
ences and standardized mean differences was taken, and for (Peto) odds ra
effect, e.g., an RR of 0.5 becomes 2.0). These transformations only chang
N 5 number of meta-analyses (number of included studies).
a Standard effect size: Cohen’s d or h.respective meta-analysis. Although there is considerable
room for improvement, an encouraging trend is the number
of trials with sufficient power that has increased over 4 de-
cades from 5% to 9%, and from 9% to 15% in trials from
significant meta-analyses. On average, sample sizes have
doubled between 1975 and 2014, whereas effect sizes did
not increase over time.Raw effect size: median (interquartile






0.20 (0.11e0.40) 0.20 (0.11e0.40)
eta-analysis is taken into account once irrespective of the number of
transformed to be unidirectional: the absolute number of risk differ-
tios and risk ratio’s effects below one were inversed (1 divided by the
e the direction and not the magnitude of the effect.
Fig. 3. Distribution plot of standardized effect sizes. Cohen’s h was
based on the proportion of events in the meta-analysis in case of
dichotomous study outcomes. In studies comparing means the stan-
dardized mean difference (Cohen’s d) of the meta-analysis was
directly available in the Cochrane database.
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0.09 and a median Cohen’s d of 0.20) shows that large effects
are rare. This information should be taken into account when
designing a clinical trial and determining the required mini-
mum sample size. The effect size summary statistics provided
here could also be used as standard prior inBayesianmodeling
inmedical research because they are based onmany thousands
of trials covering the general medical field.
Our results are in agreement with a study by Turner et al,
in which they also used the Cochrane database of system-
atic reviews (2008 version) to describe study power in clin-
ical trials [3]. This study also showed low study power with
a bimodal pattern of many low-powered studies and a small
proportion of well-powered studies. The Turner study
demonstrated a median power of 8%, whereas we find a
comparable median power of 9% across all meta-
analyses. This slightly higher percentage could be ex-
plained by the inclusion of more recent high-powered
studies, or the exclusion of meta-analyses with less than
five trials.
Our use of meta-analytic effect sizes to compute study
power has two important shortcomings. First, although it
is a fairdand the only availabledapproximation of the true
effect of a given therapy, power and sample size calcula-
tions are designed to be performed a priori. We would fully
endorse that for an individual study, there is no space for a
post hoc power computation. Second, it may be questioned
whether statistical power can be computed when the esti-
mation of the effect size includes a null effect in the 95%
CI. If there is no effect, a power calculation cannot be per-
formed. If the null hypothesis ‘‘there is no effect’’ cannot
be rejected, there is no clear effect size estimation available
as the basis for the power calculation. We have therefore
also included all results for the subset of significant meta-
analyses.
By analyzing the temporal pattern across 4 decades, we
identified an increase of study power over time. Moreover,
because effect size estimates remained stable across time,
our study clearly shows the need to increase sample sizesto design well-powered studies. A study on sample sizes
determined in preregistration on ClinicalTrials.gov between
2007 and 2010 showed that over half of the registered
studies included a required sample of 100 participants or
less in their protocol [17]. We found that, within the pub-
lished trials that have been included in a Cochrane meta-
analysis, the findings are in line with these results, and
although the average sample size has doubled since the
1970’s, and median sample size in 2010e2014 was be-
tween 150 and 180.
An argument in defense of performing small (or under-
powered) studies has been made based on the idea that
small studies can be combined in a meta-analysis to in-
crease power. Halpern et al already explained the invalidity
of this argument in 2002 [1], most importantly because
small studies are more likely to produce results with wide
CIs and large P-values, and thus are more likely to remain
unpublished. An additional risk of conducting uninforma-
tive studies is that a lack of an effect due to low power
might decrease the interest by other research teams to
examine the same effect. A third argument against perform-
ing small studies is given in a study by Nuijten et al [7],
which indicates that the addition of a small, underpowered
study to a meta-analysis may actually increase the bias of
an effect size instead of decreasing it.
There are several limitations to consider in the interpre-
tation of our results. First, the outcome parameter studied in
the meta-analysis may be different than the primary
outcome of the original study; it may have been adequately
powered for a different outcome parameter. This could
result in lower estimates of average power, although it
seems unlikely that the average effect size of the primary
outcomes is higher than the effect sizes in the Cochrane
database. Second, by contrast, effect sizes from meta-
analyses are considered to be an overestimation of the true
effect because of publication bias [7,18]. Finally, in deter-
mining the required power for a study a ‘‘one size fits
all’’ principle does not necessarily apply as Schulz and
Grimes [19] also argue. However, although conventions
are always arbitrary [12] a cutoff for sufficient power at
80% is reasonable.
With statistical power consistently increasing over time,
our data offer perspective and show that we, the scientific
community, are heading in the right direction. Nevertheless,
it is clear that most clinical trials remain underpowered.
Although there may be exceptions justifying small clinical
trials, we believe that in most cases, underpowered studies
are problematic. Clinical trials constitute the backbone of
evidence-based medicine, and individual trials would
ideally be interpretable in isolation, without waiting for a
future meta-analysis. To further improve the current situa-
tion, trial preregistrations could include a mandatory sec-
tion justifying the sample size, based on realistic
expectations of the effect size, and preferably with explicit
reference to earlier published results in the same field. If no
prior literature exists for the specific condition or treatment,
128 H.J. Lamberink et al. / Journal of Clinical Epidemiology 102 (2018) 123e128we recommend that small effects should be assumed.
Large-scale collaborations with the aim of performing
either a multicenter study or a prospective meta-analysis
may also increase sample sizes when individual teams lack
the resources to collect larger sample sizes. Another impor-
tant way to introduce long-lasting change is by improving
the statistical education of current and future scientists
[5]. Even though our analyses demonstrate that sufficient
power in clinical trials is still problematic, the situation
seems to be slowly improving. Together, these results
encourage further efforts to increase statistical power in
clinical trials to guarantee rigorous and reproducible
evidence-based medicine.
Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.jclinepi.2018.06.014.
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